Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer

Tang, Huan; Chen, Jing‐Lin; Wang, Lin; Li, Qianwen; Yang, Yue; Lv, Zhe; Bao, Haikun; Li, Yao; Luan, Xue; Yan, Li; Ren, Zhihui; Zhou, Xiaowei; Cong, Dengli; Liu, Zhiyi; Jia, Juan; Chen, Hongyu; Zhao, Weitao; Qin, Meng; Sun, Fenyong

doi:10.1016/j.ijpharm.2019.118806

Cited by 51 publications

(37 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Despite the modern therapeutic strategies that have been developed, conventional chemotherapy remains a crucial significance, including the drugs of paclitaxel (PTX), cisplatin, doxorubicin, and so on. [2][3][4] PTX is an effective drug chemotherapy in clinical treatment for BC, and the combined therapy based on PTX is usually as first-line therapy. [5][6][7] However, the acquired resistance might seriously affect the therapeutic effect to cause the eventual failure of treatment.…”

Section: Introductionmentioning

confidence: 99%

<p>Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis</p>

Liu¹,

Jiang²,

Zhang³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Paclitaxel (PTX) occupies a considerable status in the chemotherapies of breast cancer (BC), but the drug resistance keeps an obstructive factor of PTX treatment. This study was designed to explore the molecular mechanism of long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) in PTX resistance of BC. Methods: UCA1, microRNA-613 (miR-613) and cyclin-dependent kinase 12 (CDK12) expression was assayed through quantitative real-time polymerase chain reaction (qRT-PCR). Cell Counting Kit-8 (CCK-8) assay was implemented for evaluating the half inhibitory concentrations (IC 50) of PTX and cell viability. Cell apoptosis was examined by flow cytometry. The target relationship was explored using dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. CDK12 protein level was detected through Western blot. Xenograft tumor assay was applied for assessing the influence of UCA1 on PTX resistance of BC in vivo. Results: UCA1 expressed highly in PTX-resistant BC tissues and cells and regulated PTX resistance in BC cells by affecting cell viability and apoptosis in part. UCA1 negatively interacted with miR-613 and modulated PTX resistance via sponging miR-613. CDK12 was a downstream gene of miR-613 and miR-613 exerted the modulation of PTX resistance via targeting CDK12. Furthermore, UCA1 regulated CDK12 level through interacting with miR-613. The regulatory role of UCA1 in PTX resistance of BC was achieved by miR-613/ CDK12 axis in vivo. Conclusion: UCA1 mediated PTX resistance in BC through the miR-613/CDK12 axis, manifesting that UCA1 might improve the PTX treatment of BC as a significant therapeutic biomarker.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis</p>

Liu¹,

Jiang²,

Zhang³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Similar results were obtained when this combination were administered in MCF-7 cells. It was shown that at 1:1 EPI/PTX, the cells showed a synergistic effect against breast cancer cell lines [ 21 ].…”

Section: Resultsmentioning

confidence: 99%

“…It was observed that the drug release was slower in pegylated liposomal formulations of ES-SSL-EPI/PTX during a 48 h time period. It was observed that the presence of PEG resulted in lower drug release [ 21 ].…”

Section: Resultsmentioning

confidence: 99%

“…It was observed that the fluorescence intensity increased to 1.75 fold times higher as compared to SSL-EPI. The results suggested that the nanoparticle mediated drug uptake is higher as compared to the naïve form [ 21 ].…”

Section: Resultsmentioning

confidence: 99%

“…This in turn resulted in an increase efficacy of the therapeutic molecule in the cancer cells. Similarly, Tang et al reported that the IC 50 value of PTX and EPI was reduced when given in combination against breast cancer cells [ 21 ]. In another study, PTX was administered with doxorubicin (DOX) against NCL-H640 cells (lung cancer cells).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Poly-(Lactic-co-Glycolic) Acid Nanoparticles for Synergistic Delivery of Epirubicin and Paclitaxel to Human Lung Cancer Cells

Sharma

Kumari

Gupta³

et al. 2020

Molecules

View full text Add to dashboard Cite

Combination therapy using chemically distinct drugs has appeared as one of the promising strategies to improve anticancer treatment efficiency. In the present investigation, poly-(lactic-co-glycolic) acid (PLGA) nanoparticles electrostatically conjugated with polyethylenimine (PEI)-based co-delivery system for epirubicin and paclitaxel (PLGA-PEI-EPI-PTX NPs) has been developed. The PLGA-PEI-EPI-PTX NPs exhibited a monodispersed size distribution with an average size of 240.93 ± 12.70 nm as measured through DLS and 70.8–145 nm using AFM. The zeta potential of 41.95 ± 0.65 mV from −17.45 ± 2.15 mV further confirmed the colloidal stability and PEI modification on PLGA nanoparticles. Encapsulation and loading efficiency along with in vitro release of drug for nanoparticles were done spectrophotometrically. The FTIR analysis of PLGA-PEI-EPI-PTX NPs revealed the involvement of amide moiety between polymer PLGA and PEI. The effect of nanoparticles on the cell migration was also corroborated through wound healing assay. The MTT assay demonstrated that PLGA-PEI-EPI-PTX NPs exhibited considerable anticancer potential as compared to the naïve drugs. Further, p53 protein expression analysed through western blot showed enhanced expression. This study suggests that combination therapy using PLGA-PEI-EPI-PTX NPs represent a potential approach and could offer clinical benefits in the future for lung cancer patients.

show abstract

Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity

Mahabady

Mirzaei

Saebfar

et al. 2022

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer

Cited by 51 publications

References 26 publications

<p>Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis</p>

<p>Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis</p>

Poly-(Lactic-co-Glycolic) Acid Nanoparticles for Synergistic Delivery of Epirubicin and Paclitaxel to Human Lung Cancer Cells

Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity

Contact Info

Product

Resources

About